Literature DB >> 6487486

Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.

A K Salahudeen, R Wilkinson, J McAinsh, D N Bateman.   

Abstract

The elimination of atenolol (20 mg i.v.) has been studied in seven patients with renal failure on continuous ambulatory peritoneal dialysis (CAPD). Although atenolol was eliminated in the peritoneal fluid, the amount recovered in 24 h was relatively low (1.2 +/- 0.15 mg). The calculated urinary (n = 4) and peritoneal (n = 7) clearance was 0.289 +/- 0.058 l/h and 0.152 +/- 0.018 l/h respectively. This was considerably less than calculated total body clearance (1.21 +/- 0.086 l/h). The kinetics of atenolol in CAPD are worthy of further study.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6487486      PMCID: PMC1463650          DOI: 10.1111/j.1365-2125.1984.tb02490.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Metabolism of atenolol in man.

Authors:  P R Reeves; J McAinsh; D A McIntosh; M J Winrow
Journal:  Xenobiotica       Date:  1978-05       Impact factor: 1.908

2.  Kinetics and absolute bioavailability of atenolol.

Authors:  W D Mason; N Winer; G Kochak; I Cohen; R Bell
Journal:  Clin Pharmacol Ther       Date:  1979-04       Impact factor: 6.875

3.  The pharmacokinetics of single doses of metoclopramide in renal failure.

Authors:  D N Bateman; R Gokal; T R Dodd; P G Blain
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  The gas chromatographic determination of atenolol in biological samples.

Authors:  B Scales; P B Copsey
Journal:  J Pharm Pharmacol       Date:  1975-06       Impact factor: 3.765

5.  Atenolol kinetics in renal failure.

Authors:  J McAinsh; B F Holmes; S Smith; D Hood; D Warren
Journal:  Clin Pharmacol Ther       Date:  1980-09       Impact factor: 6.875

6.  Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

Authors:  B Flouvat; S Decourt; P Aubert; L Potaux; M Domart; A Goupil; A Baglin
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

  6 in total
  6 in total

Review 1.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.

Authors:  G L Traina; M G Gentile; G Fellin; R Rosina; L Cavenaghi; G Buniva; M Bonati
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis.

Authors:  A Celardo; G L Traina; M Arboix; A Puigdemont; M Bonati
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

4.  Teicoplanin pharmacokinetics in patients with chronic renal failure.

Authors:  M Bonati; G L Traina; G Villa; A Salvadeo; M G Gentile; G Fellin; R Rosina; L Cavenaghi; G Buniva
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

5.  Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.

Authors:  M Bonati; G L Traina; M G Gentile; G Fellin; R Rosina; L Cavenaghi; G Buniva
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

6.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.